Research Triangle Park, NC – Technology Commercialization Group, LLC (TCG), an international firm providing interim management and strategic advisory services to life sciences companies, announced today that it has concluded another productive quarter in 2015. Below are highlights of the firm’s second quarter 2015 accomplishments:

  • Closed two non-exclusive out-license agreements for two separate gene therapy platform technologies
  • Successfully completed a review of a clinical stage European biopharma company’s business development activities and proposed strategies for their future drug partnering campaign
  • Developed a robust valuation model and analysis of a potential investment in a new pharmaceutical startup for a Europe-based CRO
  • Representing a US-based publicly traded biotechnology company for the partnering of its oncology program
  • Successfully completed an interim CEO assignment with a publicly-traded international biotech company, helping them re-focus the company’s product portfolio and raise additional financing
  • Appointed as the interim Director of Business Development for a growing US-based contract services company
  • Named as the interim CEO of a US regenerative medicine company
  • TCG’s interim CEO of a medical device company was honored by receiving “Best Presentation Award – Lifesciences/Healthcare” at the 2015 NY Venture Summit Conference

For companies considering a strategic transaction or seeking interim management services, TCG’s depth of experience, extensive industry contacts and proven success can help you achieve your goals. Please feel free to contact us directly at our US or European offices:

USA: (919) 941-0700
Europe: +49-6221-27262